Navigation Links
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
Date:6/19/2008

uct shall no longer be covered by a valid claim of a U.S. or foreign patent or application and, generally, 10 years after the first commercial sale of any product licensed under the agreement. Wyeth may terminate the agreement without cause at any time upon 90 days' prior written notice.

Trubion retains the right to develop and commercialize, on its own or with others, product candidates directed to all targets not included within the agreement, including CD37.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
2. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
3. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
4. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
5. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
6. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
7. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
8. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
9. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
10. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
11. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... new market research report is available ... Market for Hospital-Acquired Infection Control (Sterilization, ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html ... healthcare-associated infections (HAIs), demand has increased ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 ... market research report is available in its ... Insurance in Canada, Key Trends and Opportunities ... Synopsis The report ... insights into the Canadian personal accident and ...
(Date:8/20/2014)... Aug. 20, 2014 Research and ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services ... report to their offering. ... applications and geography) - Size, Share, Global Trends, ... Segmentation and Forecast, 2013 - 2020", suggests that ...
Breaking Medicine Technology:The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 2Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 3Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 4Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 5Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 7Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 8Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 9Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 10Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 11Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 12Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 13Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 14Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 15Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 16Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 17Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 18Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 19Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 20Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 21Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 22Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 23Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
... May 21, 2012  Aushon announced its plans ... its new multiplex protein biomarker platform, which ... performance.  Aushon,s ultra-precise microarray printing, novel assay ... the sensitivity and reproducibility of single-plexed ELISA ...
... BOONTON, N.J., May 21, 2012   Unigene Laboratories, Inc. ... design, delivery, manufacture and development of peptide-based therapeutics, today ... Nozer Mehta, Ph.D., will be presenting at the TIDES ... held at the Mandalay Bay Resort and Casino in ...
Cached Medicine Technology:Aushon to Launch New Multiplex Immunoassay Platform 2Unigene to Present at TIDES 2012 2Unigene to Present at TIDES 2012 3
(Date:8/21/2014)... Relias Learning, the leader in SaaS-based training and ... announced the latest release of its flagship LMS with ... , “Supporting the Tin Can API ensures our ... learning capabilities and the ability to leverage the latest ... Jim Triandiflou, CEO of Relias Learning. “To provide our ...
(Date:8/21/2014)... ERT, a leading global ... efficacy endpoint data collection, today opened registration ... Maximizing Product Value with Optimized Endpoints. ... biopharmaceutical developers to network with leading researchers ... developing, implementing, and justifying effective strategies for ...
(Date:8/21/2014)... elicited by T-type calcium channels in the thalamic ... of calcium. These channels enable thalamic reticular nucleus ... to enter a hyper-excited state. , In order ... absence seizures, the researchers conducted an experiment to ... techniques to delete the T-type calcium channel CaV3.3. ...
(Date:8/21/2014)... we put on in the morning? Do we drive to ... we want to buy lunch? We make hundreds of different ... minimal impact, it is extremely important for our long-term personal ... People with ADHD often find this difficult, however. They are ... a prompt but smaller reward instead of making a choice ...
(Date:8/21/2014)... 21, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
Breaking Medicine News(10 mins):Health News:Relias Learning Announces Support for Tin Can API 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 3Health News:ADHD children make poor decisions due to less differentiated learning processes 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5
... minister of Ireland has asked the health officials to review ... after an inquiry was probed in to the matter of ... killed by her mentally ill boyfriend Paul McCleery in March ... is a voluntary patient of mental health services provided by ...
... The case of an 11-year-old girl who is all set to ... shocked and frustrated health experts who maintain// that it is her ... whose identity is not being disclosed for legal reasons, is a ... pregnant after indulging in intercourse while on a drinking binge. The ...
... Madhya Pradesh has stated that more than 70 percent of ... of curriculum in schools//. ,The Madhya Pradesh Voluntary Health ... 10 to 19 years in 12 districts of the state. ... the awareness would help them remain healthy and not get ...
... a new study, oral and intravenous antiviral drug may ... ,Shingles, which is caused by varicella-zoster virus, is ... researchers at the University of Colorado and Health Sciences ... and three women with moderate to severe pain following ...
... been bitten by a bat and subsequently diagnosed with rabies has ... treatment is being offered, the chances of the boy recovering is ... student of Humble High School fell ill last week, unaware of ... this could happen, a bat had flown into his house while ...
... have been discovered by scientists at UCSF, Celera Genomics and ... risk// for early heart attack, or myocardial infarction (MI). ... a protein essential for early stages of clotting. When clotting ... heart attack. Knowing gene mutations that increase heart attack risk ...
Cached Medicine News:Health News:Health Experts Shocked As 11-year-old Girl To Be UK's Youngest Mother 2Health News:Girls In MP Want Sex Education In Schools: Health Survey 2Health News:Gene Variants Linked to Early Heart Attack Discovered 2Health News:Gene Variants Linked to Early Heart Attack Discovered 3Health News:Gene Variants Linked to Early Heart Attack Discovered 4
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines ...
Indications For Usage: , ,For use during pulmonary lung function testing...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
Medicine Products: